Vorasidenib Demonstrates Sustained Long-Term Efficacy in IDH-Mutant Grade 2 Glioma
核心洞察
Extended follow-up data from the phase 3 INDIGO trial confirms vorasidenib's durable treatment benefit, with median progression-free survival not estimable versus 11.4 months for placebo.
The targeted therapy significantly reduced tumor growth rate and seizure frequency compared to placebo, with only 32% of vorasidenib patients experiencing disease progression versus 64% on placebo.
Safety profile remained manageable with fewer than 5% of patients discontinuing treatment due to adverse events and no treatment-related deaths reported.
Vorasidenib (Voranigo) maintained durable treatment benefits in patients with grade 2 IDH1 (搜索)/2-mutant glioma following surgical resection, according to extended follow-up data from the phase 3 INDIGO trial published in The Lancet Oncology. The analysis included an additional six months of placebo-controlled, double-blind data collected between September 6, 2022, and trial unblinding on March 7, 2023.
Sustained Progression-Free Survival Benefit
At a median follow-up of 20.1 months, vorasidenib significantly improved progression-free survival (PFS), the trial's primary endpoint. The median PFS was not estimable (95% CI, 22.1-NE) in the vorasidenib arm compared with 11.4 months (95% CI, 11.1-13.9) in the placebo arm (HR, 0.35; 95% CI, 0.25-0.49; P < .0001). Imaging-based disease progression per blinded independent review committee occurred in 32% of patients receiving vorasidenib versus 64% of those receiving placebo.
Prespecified subgroup analyses demonstrated consistent PFS benefit across all evaluated patient subgroups, uniformly favoring vorasidenib over placebo. The treatment also significantly improved the key secondary endpoint of time to next intervention (TTNI), with median TTNI not estimable for vorasidenib compared with 20.1 months for placebo (HR, 0.25; 95% CI, 0.16-0.40; P < .0001).
Reduced Tumor Growth and Seizure Activity
Beyond progression-free survival, vorasidenib demonstrated additional clinical benefits. The treatment was associated with reduced tumor growth rate and lower seizure frequency compared with placebo, without detrimental effects on health-related quality of life or neurocognitive function.
Exploratory analyses revealed particularly striking results for seizure control. Among patients who experienced one or more seizures, the rate of on-treatment seizures per person-year was significantly lower with vorasidenib (18.2 seizures per person per year; 95% CI, 8.4-39.5) than with placebo (51.2 seizures per person per year; 95% CI, 22.9-114.8; P = .026).
Trial Design and Patient Population
The INDIGO trial was a global, randomized, double-blind, placebo-controlled study conducted across 11 countries. The study enrolled 331 patients aged 12 years or older with residual or recurrent grade 2 IDH1 (搜索)/2-mutant diffuse glioma who had undergone surgery as their only prior treatment. Patients were randomly assigned 1:1 to receive oral vorasidenib at 40 mg once daily (n = 168) or placebo (n = 163) in continuous 28-day cycles until disease progression or unacceptable toxicity.
Among the enrolled population, 172 patients had oligodendroglioma (搜索) (vorasidenib, n = 88; placebo, n = 84) and 159 had astrocytoma (搜索) (vorasidenib, n = 80; placebo, n = 79). Randomization was stratified by locally determined chromosome 1p/19q codeletion status and baseline tumor size.
Safety Profile Remains Manageable
The safety profile of vorasidenib was consistent with previously reported data. The most frequently reported grade 3 or higher treatment-emergent adverse effects included elevations in alanine aminotransferase levels (10%), elevations in aspartate aminotransferase levels (5%), seizures (4%), and elevated gamma-glutamyltransferase levels (3%). These effects were manageable with standard supportive measures and dose modifications when necessary.
Importantly, fewer than 5% of patients discontinued therapy due to adverse events, and no treatment-related deaths occurred during the study period. No new safety signals were detected in the extended follow-up analysis.
Clinical Impact and Future Outlook
"For decades, patients with grade 2 IDH-mutated gliomas had limited treatment options. While surgery was often the first-line treatment option for glioma, total resection was rarely achievable because tumors continue to grow and infiltrate the brain even after surgery," said Timothy Cloughesy, MD, of the David Geffen School of Medicine Department of Neurology at UCLA and an investigator for the INDIGO trial. "The longer-term data from the INDIGO trial demonstrate that targeted IDH inhibition can fundamentally alter the growth trajectory of certain gliomas, leading to gradual tumor shrinkage."
Vorasidenib received FDA approval in August 2024 after receiving Fast Track Designation, becoming the first and only FDA-approved targeted treatment for grade 2 IDH-mutant glioma. The phase 3 INDIGO trial continues, with Servier planning to present longer-term follow-up results from what they describe as the largest dataset to date in IDH-mutant glioma.
"These longer-term results from the INDIGO trial build upon vorasidenib's previously demonstrated clinical benefits and demonstrate reductions in tumor volume and seizure frequency in patients with IDH-mutated gliomas," said Becky Martin, PhD, chief of Medical at Servier Pharmaceuticals. "One year after the FDA approval of vorasidenib, we're immensely proud to have delivered this first-of-its-kind targeted therapy to thousands of patients living with IDH-mutated glioma, offering them clinically meaningful and durable treatment benefits supported by more than a decade of research."